FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Company ProfileAura Biosciences, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AURA
Aura Biosciences, Inc. Stock AnalysisComprehensive stock analysis for Aura Biosciences, Inc. (AURA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAURA
AURA
Aura Biosciences, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AURA
Home🔹Stocks🔹Aura Biosciences, Inc.

Aura Biosciences, Inc.

🇺🇸AURA•NASDAQ

Aura Biosciences, Inc.

🇺🇸AURA•NASDAQ
Market cap
$640.90M
Sentiment

Your view on AURA

Mkt Cap
$640.90M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Aura Biosciences, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Elisabet de los Pinos
Headquarters
85 Bolton Street, Boston, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Elisabet de los Pinos
Headquarters
85 Bolton Street, Boston, MA, US
Description

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.

It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Aura Biosciences, Inc., and the rating behind it. AURA last traded at $6.18; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Aura Biosciences, Inc.. Starting points for Aura Biosciences, Inc.: EPS -$1.38, beta 0.41 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Aura Biosciences, Inc.. Aura Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Aura Biosciences, Inc.. Trailing twelve-month EPS for Aura Biosciences, Inc. stands at -$1.38. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Aura Biosciences, Inc.. Aura Biosciences, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Aura Biosciences, Inc. valued side by side against its closest peers. Aura Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Aura Biosciences, Inc., and how their positions are changing. At a $640.9M market value, institutional positions materially move Aura Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Aura Biosciences, Inc. executives and directors. Shares of Aura Biosciences, Inc. have traded between $4.34 and $9.53 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Aura Biosciences, Inc.. Aura Biosciences, Inc. is a $640.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Aura Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Aura Biosciences, Inc.. Coverage tracks Aura Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

Peer companies

  • BCYCBicycle Therapeutics plc
  • CRBPCorbus Pharmaceuticals Holdings, Inc.
  • EYPTEyePoint Pharmaceuticals, Inc.
  • IMNMImmunome, Inc.
  • MGNXMacroGenics, Inc.
  • OCGNOcugen, Inc.
  • OCSOculis Holding AG

More Biotechnology companies

  • MREOMereo BioPharma Group plc
  • MRESInstitute of Biomedical Research Corp.
  • MRKRMarker Therapeutics, Inc.
  • MRNAModerna, Inc.
  • MRPIMera Pharmaceuticals, Inc.
  • MRVIMaravai LifeSciences Holdings, Inc.
  • MRVL.VMarvel Biosciences Corp.
  • MRZMMarizyme, Inc.
  • MSB.AXMesoblast Limited
  • MSCL.TOSatellos Bioscience Inc.
  • MSLESatellos Bioscience Inc.
  • MSRMMushrooms Inc

ETFs holding Aura Biosciences, Inc.

Largest holders, then the funds most concentrated in AURA · % = share of the fund

  • VTIVanguard Total Stock Market ETF0.00%
  • IWMiShares Russell 2000 ETF0.01%
  • VXFVanguard Extended Market ETF0.01%
  • XBIState Street SPDR S&P Biotech ETF0.06%
  • BBCVirtus LifeSci Biotech Clinical Trials ETF0.80%
  • IWCiShares Micro-Cap ETF0.09%
  • GWXState Street SPDR S&P International Small Cap ETF0.06%
  • SCHCSchwab International Small-Cap Equity ETF0.04%
AURA Analysis
Fair
Past2
Growth2
Health4
Profit1
Value1

News

Latest Market News

No comments yet

Be the first to ask a question or say what you make of Aura Biosciences, Inc.